ClinicalTrials.gg
Not yet recruitingNCT06712199Updated Dec 2, 2024

Effect of Oxalidine Combined with Reduced-opioid Anesthesia on Multimodal Analgesia in Morbidly Obese Patients Undergoing Bariatric Surgery

A Phase 4 interventional study of oxalidine in Morbid Obesity, sponsored by Yongtao Sun. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by Yongtao Sun · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Obesity, Morbid with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Obesity, Morbid · China.

Started
2025
with 2 others
Phase 4
Only one
of the 10
Registered
7th of 10
by date
Lead sponsor
2 of 10
Yongtao Sun

Among the 10 studies in Obesity, Morbid with a site in China, this one is one of 3 that started in 2025, is the only one in phase 4, and was the 7th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

4 of the 10 studies in Obesity, Morbid with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Obesity, Morbid with a site in China, or all of them as a file.
02

Study summary

The goal of this study is to elucidate the efficacy and safety of oxelidine combined with oligopiate anesthesia for multi-modal analgesia in weight-loss surgery in morbidly obese patients, and to discover a new strategy for multi-modal analgesia management in weight-loss surgery, laying a foundation for the widespread application of oligopiate anesthesia in special patients.

A total of 124 patients who underwent elective bariatric surgery in our hospital were selected, and the participants were randomly divided into two groups: the opioid anesthesia group (OBA group) and the low-opioid anesthesia group (OFA group) using a random number table to achieve simple randomization.

Inclusion criteria: 1.ASA grade I \~ III; 2. Age ≥18 years old; 3. Bariatric surgery patients with BMI≥35kg/m2 and complex signs of morbid obesity (such as metabolic syndrome) 4. Sign the informed consent form.

Exclusion criteria: 1. Positive pregnancy test or breastfeeding; 2. Patients with a history of substance abuse or dependence on opioids; 3. Patients with chronic pain or with severe heart, lung, liver or nervous system diseases.

Anesthesia implementation: 1. Routine monitoring after entry, intravenous administration of midazolam and atropine. Study participants were placed in the ramp position, bilateral recurrent laryngeal nerve block under ultrasound guidance, and the mouth contained dachronine gel. Radial artery puncture was performed and dexmedetomidine was injected intravenously. A laryngeal tube is used to test the sensation of the back of the oropharynx, and a laryngeal mask is placed while awake to connect the anesthesia circuit and deliver oxygen. Once the vocal cords are seen and the end-respiratory CO2 waveform is observed.

  1. The OBA group underwent combined anesthesia induction with propofol, rocuronium bromide and sufentanil, endotracheal intubation through visual laryngeal mask, intraoperative pump injection of propofol and remifentanil to maintain anesthesia, sufentanil bridging 10μg 30 minutes before the end of the operation; In OFA group, propofol, rocuronium bromide and esketamine were induced by combined anesthesia, and endotracheal intubation was performed through visual laryngeal mask. Intraoperative pump propofol and esketamine to maintain anesthesia; Oxeridine was bridged-1.5 mg 30min before the operation and administered in two doses, 0.75mg/ time, with an interval of 10min.
  1. Both groups were subjected to bilateral lower costal margin transversal nerve block under ultrasound guidance.
  1. Ondansetron was given before the end of the operation. After the operation, the tracheal cannula was removed under deep anesthesia, and the laryngeal mask was retained and transferred to the postoperative resuscitation room. Sugengosaccharide sodium was used to antagonize muscle pine during recovery. After the study participants were awake, the laryngeal mask was well tolerated. The laryngeal mask was removed after observation for 1h, and the laryngeal mask was safely transferred to the ward after continuous observation for 1h.

PCA administration regimen in OBA group: Sufentanil + dexmedetomidine + Ondansetron; OFA group PCA administration regimen: oxelidine + dexmedetomidine + Ondansetron. Record the number of compressions, if the assessment of NRS≥4 points, then remedy 2mg oxycodone hydrochloride, and record the dosage.

Main outcome measures: Consumption of oral morphine equivalent (OME) opioids in the 24 hours prior to surgery.

Secondary outcome measures: Overall satisfaction with analgesia and Numerical Rating Scale (NRS, 0-10) pain score, area under the curve of resting and exercise NRS score (AUC) within 72 hours after surgery, time to first use of rescue analgesics within 72 hours, cumulative opioid consumption 72 hours after surgery (morphine milligram equivalent, morphine milligram equivalent, NRS score) MME), participants' satisfaction with postoperative analgesia, 15-item Quality of Recovery score Scale (QoR15) at 24, 48, and 72h after surgery, incidence of postoperative complications, incidence of nausea and vomiting, and incidence of adverse events were recorded.

Read the detailed description

In this study, sample size was calculated according to the method of comparing two independent samples from PASS software. A Ahmed SA[1] -based study (an effect of opioid-free anesthesia on postoperative opioid consumption during laparoscopic bariatric surgery: a randomized controlled double-blind study focusing on morphine consumption in the first 24h) was 5.8±1.9mg in the first 24 hours in the OFA group compared with 7.2 ± 2.3 mg in the OBA group. Set bilateral α =0.05, the grasp (1- β) is 90%. The sample size consisted of 49 patients in the OFA group and 49 patients in the control group. Considering 20% loss and refusal, at least 124 cases were included.

This study is a single-center, single-blind, randomized controlled study, select patients undergoing elective weight loss surgery in our hospital, and preoperative screening eligible study participants will voluntarily sign written informed consent before randomization. The study physician is responsible for assigning the interventions. Before the study participants entered the operating room, the special researchers who did not participate in the clinical observation realized the simple randomization method with a random number table. The study participants were randomly divided into two groups. The results were stored in an opaque envelope and not opened until 20 minutes before the start of anesthesia, and the drug extraction and preparation were performed. We selected the same group of surgeons to perform weight-loss surgery for the study participants.

Pre-anesthesia preparation: All study participants considered difficult airway and general anesthesia was placed under a visual laryngeal mask during awake descent. Routine monitored after transport to the operating room, midazolam 2 mg and atropine 0.4 mg were administered intravenously. Study participants placed slope position, ultrasound-guided bilateral recurrent laryngeal nerve block, injected 0.375% ropivacaine 2 mL, 10 mL mouth containing 10min. Monitoring invasive arterial blood pressure under local anesthesia, dexmedetomidine (load amount 1 μ g · kg-1 · 10min-1, maintenance amount 0.5 μ g · kg-1 · h-1 to 40min before the end of surgery). Test the sensation of the back of the oropharynx with a anesthetic tube. If there is a nausea reflex, locally spray 2% lidocaine 2 mL in the back of the oropharynx with a tube. The laryngeal mask model was selected according to the lean body weight of the study participants, and the laryngeal mask was placed in the awake state. All the study participants were well tolerated, connected to the anesthesia circuit, and delivered 100% oxygen. Once the vocal cords are seen, and the terminal respiratory carbon dioxide waveform is observed.

anesthesia induction: Opioid anesthesia group (OBA group): propofol 2.5mg · kg-1, rocuronium and 0.6mg · kg-1 and sufentanil 0.3 μ g · kg-1 combined anesthesia induction, endotracheal intubation through visual laryngeal mask when BIS value reaches 40-60; Less opioid anesthesia group (OFA group): propofol 2.5mg · kg-1, rocuronium and 0.6mg · kg-1 and esketamine 0.3mg · kg-1 combined anesthesia induction, endotracheal intubation through visual laryngeal mask when BIS value reaches 40\~60; Participants in both groups retained laryngeal mask evacuated cuff gas and applied endotracheal intubation to maintain anesthesia. Select 0.375% ropivacaine 40 mL, both groups were compound ultrasound guided downward bilateral inferior transverse abdominal muscle nerve block.

continuous anesthesia: Opioid anesthesia group (OBA group): pump propofol 4-12 mg · kg-1 · h-1 and remifentanil 0.2-0.5 μ g · kg-1 · min-1 for maintenance anesthesia; bridge sufentanyl 10 μ g 30min before surgery.

Less-opioid anesthesia group (OFA group): pump propofol 4-12 mg · kg-1 · h-1 and esketamine 0.3\~0.5mg · kg-1 · h-1 maintenance anesthesia; bridging oslilidine 1.5mg 30min before surgery, 0.75mg / dose, 10min interval.

Both groups were ventilated with tidal volume of 6 \~ 8 mL/Kg to avoid barotrauma, respiratory rate 10\~14 breaths / min, positive end-expiratory pressure (PEEP) 5\~10 cmH2O to maintain PETCO2 35\~45 cmH2O. We considered hemodynamic instability as SAE (vasoactive drugs for hypotension or hypertension, atropine for bradycardia, β blockers for tachycardia) and recorded the number of treatments. Ondansetron (8mg, iv) was given 20 min before the end of the operation. After surgery, the endotracheal intubation was removed under deep anesthesia, and the laryngeal mask was retained and transferred to the postoperative resuscitation room (PACU). During the resuscitation period, 2 to 4 mg · kg-1. After the study participants were awake, the laryngeal mask was well tolerated, and the laryngeal mask was removed 1h after observation and safely transferred to the ward after further observation for 1h.

Postoperative pain management:

PCA dosing regimen in the opioid anesthesia group (OBA group): sufentanyl 2 µ g / kg + dexmedetomidine 2 µ g / kg + ondansetron 24mg; PCA dosing regimen in the less-opioid anesthesia group (OFA group): Osiidine 30mg + dexmedetomidine 2 µ g / kg + ondansetron 24mg.

Both groups were configured to 100ml, with a background dose of 2ml / h, a bolus volume of 0.5ml / time, and a locking time of 15min. Record the number of presses, if you evaluate the NRS 4 points, remedy oxycodone hydrochloride 2mg, and record the dosage.

Study intervention program Opioid Anesthesia Group (OBA group) Propofol 2.5mg · kg-1, rocuronium and 0.6mg · kg-1 and sufentanil 0.3 μ g · kg-1 for BIS at 40-60; pump propofol 4-12 mg · kg-1 · h-1 and remifentanil 0.2\~0.5 μ g · kg-1 · min-1 to maintain anesthesia; 10 μ g 30min before surgery. PCA dosing regimen: sufentanyl 2 µ g / kg + dexmedetomidine 2 µ g / kg + ondansetron 24mg.

Less-opioid anesthesia group (OFA group) Propofol 2.5mg · kg-1, rocuronium and 0.6mg · kg-1 and esketamine 0.3mg · kg-1 combined anesthesia induction, tracheal intubation at 40-60; pump propofol 4-12 mg · kg-1 · h-1 and esketamine 0.3\~0.5mg · kg-1 · h-1; maintain anesthesia, bridging Osilidine 1.5mg 30min before surgery, administered twice, 0.75mg / time, 10min interval. PCA dosing regimen: Oliidine 30mg + dexmedetomidine 2 µ g / kg + ondansetron 24mg.

Determination of analgesic effect and analgesic remedial measures During hospitalization, if NRS score 4,2mg for rescue analgesia; if score 7 exceeds 24h, this will be defined as an adverse event and all details will be recorded in the CRF.

Recording and handling of adverse events Pain: If the NRS score is ≥4, 2mg oxycodone should be injected intravenously for rescue and analgesia.

Agitation: The assessment was made using the Richmond Agitation sedation Score (RASS). If the score was ≥+2, sedation was given (dexmedetomine drops were given according to body weight).

Delirium: The 3D-CAM delirium scale was used to assess, and if delirium occurred, sedation was administered (dexmetopidine intravenous drops according to body weight); Respiratory depression: defined as SpO2 \< 90%, if respiratory depression occurs, immediately adjust the oxygen flow, mask pressure ventilation if necessary; Respiratory depression should be monitored during anesthesia induction and recovery to ensure the safety of study participants.

Delayed recovery: defined as residual sedation for more than 30 minutes after withdrawal, where appropriate, flumaxinil antagonism is given; Postoperative chills: Wrench standard grading: 0, no chills; Grade 1, fasciculus and/or peripheral vascular constriction and/or peripheral cyanosis, but no muscle fibrillation; Grade 2, only one muscle group fibrillation; Grade 3, more than one muscle group muscle fibrillation; Level 4, generalized fibrillation. Wrench score ≥3 is defined as the occurrence of chills. If study participants developed chills, they were treated with pethidine hydrochloride injection; Postoperative nausea and vomiting: PONV was assessed using grades (grade 1: mild nausea, abdominal discomfort, but no vomiting; Grade 2: transient vomiting, vomiting ≤1 time; Grade 3: Vomiting requiring medical treatment, vomiting ≤2 times; Grade 4: Medically difficult to control vomiting, vomiting ≥3 times.) 4.3.6.8 Fluctuations in Blood pressure: When systolic blood pressure (SBP) drops by more than 20% of the baseline value or less than 90mmHg, norepinephrine is given 4μg; When the increase of SBP was more than 20% of the basic value or more than 180mmHg, urapidil 12.5-25 mg was given; 4.3.6.9 Heart rate change: Atropine was given 0.3 \~ 0.5mg when HR \< 50 times/hour; HR > 100 times/hour, Esmolol 0.5mg/kg, can be repeated if necessary.

4.3.6.10 Oxelidine overdose or intoxication: presentation of pinpoint pupil, respiratory depression or hypotension. Rescue methods first keep the airway unobstructed, and then give the corresponding support therapy, improve ventilation, oxygen and so on. The relief drug is naloxone, 0.4mg-0.8mg, intravenous injection, necessary time interval 2-3min repeated administration.

03

Conditions studied

  • Morbid Obesity

Browse trials for

Keywords

  • Oxeridine
  • Hypopiate anesthesia
  • Multimodal analgesia
  • Morbid obesity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing weight loss surgery under general anesthesia;
  • Age ≥18 years old;
  • ASA Grade I-III;
  • ≥35kg/m2 with complex signs of morbid obesity (such as metabolic syndrome)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy test positive or breastfeeding;
  • Patients with a history of substance abuse or dependence on opioids;
  • Patients with chronic pain or with severe heart, lung, liver or nervous system diseases.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
124 participants (estimated)

Study arms

  • Placebo comparator
    Opioid Anesthesia Group (OBA Group)

    In OBA group, propofol, rocuronium bromide and sufentanil were induced by combined anesthesia, tracheal intubation was performed through a visual laryngeal mask, propofol and remifentanil were injected into the intraoperative pump to maintain anesthesia, and sufentanil was brided to 10μg 30 minutes before the end of the operation. PCA administration regimen in OBA group: Sufentanil + dexmedetomidine + Ondansetron.

    Drug: oxalidine

  • Experimental
    Less opioid anesthesia Group (OFA group)

    In OFA group, propofol, rocuronium bromide and esketamine were induced by combined anesthesia, and endotracheal intubation was performed through visual laryngeal mask. Intraoperative pump propofol and esketamine to maintain anesthesia; Oxeridine was bridged-1.5 mg 30min before the operation and administered in two doses, 0.75mg/ time, with an interval of 10min.

    Drug: oxalidine

Interventions

  • Drugoxalidine

    Opioid anesthesia group (OBA group) Anesthesia was induced with propofol 2.5mg·kg-1, rocuronium 0.6mg·kg-1 and sufentanil 0.3μg·kg-1. When BIS value reached 40-60, tracheal intubation was performed through visual laryngeal mask airway. Anesthesia was maintained with propofol 4-12 mg·kg-1·h-1 and remifentanil 0.2-0.5 μg·kg-1·min-1. Sufentanil 10μg was bridaged 30min before the end of surgery. The PCA dosing regimen was sufentanil 2 µg/kg+ dexmedetomidine 2 µg/kg+ ondansetron 24mg. Reduced-opioid anesthesia group (OFA group) Anesthesia was induced with propofol 2.5mg·kg-1, rocuronium 0.6mg·kg-1 and esketamine 0.3mg·kg-1. When BIS value reached 40-60, tracheal intubation was performed through visual laryngeal mask airway. Propofol 4-12 mg·kg-1·h-1 and esketamine 0.3-0.5 mg·kg-1·h-1 were pumped to maintain anesthesia during operation. Oxalidine 1.5mg was given in two divided doses of 0.75mg each time with an interval of 10min 30min before the end of surgery. The PCA regimen was as follows:

    Also known as: Less opioids for anesthesia

06

What researchers measure

Primary outcomes

  1. Oral morphine equivalent (OME) opioid consumption in the 24 hours prior to surgery

    Time frame: 24 hours after surgery

Secondary outcomes

  1. Area under the NRS score curve at rest and exercise 72 hours after surgery (AUC)

    Area under the NRS score curve at rest and exercise 72 hours after surgery (AUC)

    Time frame: Within 72 hours after surgery

Other outcomes

  1. Overall satisfaction with analgesia and Numerical Rating Scale (NRS, 0-10) pain scores, study participants' satisfaction with postoperative analgesia, 15-item Quality of Recovery score Scale (QoR15) at 24, 48, and 72h after surgery

    Numeric Rating Scale (NRS) pain score was used to evaluate the degree of pain. According to the degree of self-rating on a 10-point scale, a total of 1-10 points, according to the corresponding numbers can be divided into different degrees of pain, that is, 0 is no pain, 1 to 3 is mild pain, 4 to 6 is moderate pain, 7 to 10 is severe pain. study participants' satisfaction with postoperative analgesia, The QoR-15 scale, which ranges from 0 (very poor quality of recovery) to 150 (excellent quality of recovery), can visually reflect the postoperative recovery status of patients. In addition, the scale has high reliability and validity, and the assessment time is relatively short, usually 3-4 minutes, which facilitates its wide application in clinical practice.

    Time frame: 72 hours after surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Dec 2026, 23 months later.

Of 28 phase 4 interventional studies under Obesity, Morbid, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2024
First posted
Dec 2, 2024
StartEst.
Jan 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06712199
Lead sponsor
Yongtao Sun
Collaborators
The First Hospital affiliated of Shandong First Medical University
Responsible party
Yongtao Sun (professor, Qianfoshan Hospital) — Sponsor-investigator
First posted
Dec 2, 2024
Start date
Jan 1, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 2, 2024

Study contacts

yong tao Sun, ph.d
Contact
sunyongtao1979@163.com
18660795201

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion